40 results
Page 2 of 2
6-K
EX-10.1
otjirjj2
21 Dec 22
Current report (foreign)
7:45am
6-K
EX-99.1
f45o7zejb6ba haum
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
6-K
EX-99.1
lpdatzfudgjo
5 Jan 22
Current report (foreign)
7:30am
6-K
EX-99.1
1s99 oxbfqt
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
2hy9 5k3jyicffi6
1 Mar 21
Current report (foreign)
12:00am
6-K
gg0wx
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
iy2cquwp
20 Jul 20
from 6-K
9:02am
6-K
EX-99.2
m8jwfbc
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
20-F/A
yiynkcw y2h
29 Mar 19
Annual report (foreign) (amended)
4:23pm
6-K
EX-99.2
k4k8 3grp
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.2
mm01xw
9 Aug 18
Current report (foreign)
7:35am
6-K
EX-99.2
epms5a6juept8
17 May 18
Current report (foreign)
7:45am
424B4
0vi0myq8xa6
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
43iisfa2kt
2 May 18
Registration statement (foreign)
7:10am
F-1
EX-1.1
1o6qd
2 May 18
Registration statement (foreign)
7:10am
20-F
kk4wg30 xd
29 Mar 18
Annual report (foreign)
12:00am